BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

NCT00528567 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2591

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab
DRUG: Standard adjuvant chemotherapy

Sponsor

Hoffmann-La Roche